Upadacitinib
Switching from adalimumab to upadacitinib demonstrates clinical improvement for patients with RA
PHILADELPHIA — An early switch from adalimumab to upadacitinib due to non-response demonstrated clinical improvement among patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.
Upadacitinib effective in patients with RA who failed prior TNF inhibitor therapy
PHILADELPHIA — Among patients with rheumatoid arthritis who had an inadequate response or intolerance to TNF inhibitors, upadacitinib demonstrated clinically meaningful and improved efficacy over 24 weeks, according to a post-hoc analysis.
Upadacitinib shows greater improvement in PsA compared with adalimumab, placebo
PHILADELPHIA — In patients with psoriatic arthritis, upadacitinib showed greater improvement compared with both placebo and adalimumab as assessed by the Routine Assessment of Patient Index Data 3, or RAPID3, scores.
Frequent switching between JAK inhibitors observed in patients with RA
PHILADELPHIA — Patients with rheumatoid arthritis frequently switched between JAK inhibitors in Australia, according to a presentation at ACR Convergence 2022.
Upadacitinib has ‘favorable’ benefit-risk profile for atopic dermatitis
Upadacitinib was well tolerated with no new important safety risks among patients with moderate to severe atopic dermatitis treated for approximately 1 year, according to a study published in The Journal of Allergy & Clinical Immunology.
Higher-dose upadacitinib reduces disease severity, prolongs clinical remission in UC
CHARLOTTE, N.C. — A higher dose of upadacitinib decreased disease severity and induced clinical remission for a longer period among patients with active ulcerative colitis, according to a presenter at ACG Annual Scientific Meeting.
FDA approves upadacitinib for non-radiographic axial spondyloarthritis
The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis, marking the sixth indication for the therapy, according to a press release from AbbVie.
Upadacitinib significantly improves non-radiographic axial SpA signs, symptoms vs placebo
Upadacitinib demonstrated significant improvements in patients with non-radiographic axial spondyloarthritis when compared with a placebo at 14 weeks, according to data published in The Lancet.
Upadacitinib efficacious in patients with ankylosing spondylitis refractory to biologics
Upadacitinib is efficacious over 14 weeks in patients with ankylosing spondylitis who mounted poor responses to biologic disease-modifying antirheumatic drugs, according to data published in the Annals of the Rheumatic Diseases.
‘PsA doesn’t happen by itself’: Importance of multidisciplinary management
For patients with psoriatic arthritis, collaboration between a dermatologist and rheumatologist is integral to receiving optimal care.